VJOncology is committed to improving our service to you

ASCO 2017 | Results of a Phase III trial on CT-P6, a trastuzumab biosimilar candidate, in early breast cancer

VJOncology is committed to improving our service to you

Justin Stebbing

Justin Stebbing, MD, PhD from Imperial College Healthcare NHS Trust, UK, presents results from a double-blind phase III study comparing the efficacy and safety of CT-P6, a trastuzumab biosimilar candidate, versus traztuzumab as neoadjuvant treatment in HER2-postivie early breast cancer.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter